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Abstract
Purpose To evaluate the in vivo effect of adding gefitinib
to preoperative chemotherapy on the EGFR-dependent
p42/44 MAPK in operable breast cancer (BC) patients.
Secondary aims: to evaluate EGFR, (p)-EGFR, Ki67,
apoptotic index (TUNEL test) and VEGFR2 expression
from baseline to surgery, percentage of pathologic com-
plete response (pCR), and toxicity.
Patients and Methods 90 patients with stage II-IIIA BC
have been randomized to receive epirubicin 90 mg/sqm and
paclitaxel 175 mg/sqm on day 1 plus: gefitinib 250 mg daily
from day 5 to 16 (Arm A, intermittent), gefitinib 250 mg daily
from day 1 to 21 (Arm B, continuous), or placebo (Arm C).
Treatment plan: 4 courses every 3 weeks, followed by surgery.
Results After preoperative therapy, 86/90 patients under-
went surgery; 46 patients (51%) received breast conservative
surgery. A pCR was observed in 4 patients. No significant
differences in the expression of p42/44 MAPK, EGFR,
(p)-EGFR, VEGFR2, proliferation index and apoptosis were
observed comparing the combined Arms A + B vs C, and
comparing Arm A vs B. Hematologic toxicities were not
significantly different comparing Arms A + B vs Arm C, and
comparing Arm A vs B. Significantly higher skin and
mucosal toxicities were observed when comparing the two
gefitinib Arms (A + B) vs Arm C (32% vs 9.6%, P = 0.018;
57% vs 29%, P = 0.009 respectively), while no significant
differences were observed comparing Arm A vs B.
Conclusion Adding gefitinib to chemotherapy did not
result in different effects on the EGFR-dependent pathway,
proliferation, apoptosis and VEGFR2 expression as com-
pared to placebo, while enhancing skin and mucosal
toxicity. The two schedules of gefitinib (intermittent vs
continuous) did not result in different biologic effects.
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Introduction
The epidermal growth factor receptor (EGFR) is a trans-
membrane tyrosine kinase receptor of the ErbB family. The
aberrant activation of this receptor leads to increased pro-
liferation and angiogenesis, and reduced apoptosis [1].
EGFR is expressed by several epithelial tumors, and in
breast cancer the positivity rate ranges between 14 to 91%
[2]. The overexpression of EGFR has been associated with
more aggressive breast cancer phenotype, and poorer
patient outcome. In contrast to the other ErbB family
member HER2, a standardized assay to determine the
EGFR status has not been developed, neither a predictive
marker for response to anti-EGFR therapies. Moreover,
besides the EGFR over-expression, the activation of the
EGFR signaling pathway can be due to different mecha-
nisms including the over-expression of EGFR ligands, the
mutation of EGFR which results in a constitutively acti-
vated form of EGFR, or the heterodimerization with other
members of the ErbB family [3–6]. Therefore, the sole
measurement of the EGFR expression does not completely
encompass the possible role of the EGFR pathway on
tumor aggressiveness.
Gefitinib is an orally available, low molecular weight,
reversible tyrosine kinase inhibitor of the EGFR, that has
documented activity in NSCLC [7–9]. In this disease, the
activity of this agent is dependent from the tridimensional
structure of the EGFR ATP cleft more than its level of
expression [10].
Gefitinib has been tested also in advanced breast cancer
both in monotherapy, and in combination with chemo-
therapy, with limited activity [11–14].
However, early trials with targeted therapies have shown
that lack of activity in advanced stages and in heavily
pretreated patients may not predict the efficacy in earlier
stages of the disease. In fact, these agents predominently
act by inhibiting cell proliferation instead of inducing
apoptosis, therefore their maximum therapeutic effect
might occur in the presence of low tumoral burden.
Primary systemic therapy, besides the proven advantage
of increasing the chance for breast-conservative surgery, is
the ideal model to test the activity and the efficacy of
molecularly targeted agents. In fact, by evaluating the
expression of tissue biomarkers before and after treatment,
this strategy offers the unique opportunity to directly test
in vivo the interactions between drugs and the tumor
microenvironment, and their potential relations with tumor
response and patient outcome.
We have therefore designed a randomized phase II
multicentric trial with gefitinib plus chemotherapy as pre-
operative treatment for operable breast cancer.
Methods
Patient selection
Patients with histologically proven, previously untreated,
primary breast cancer were eligible for this study if they
met the following criteria: stage II–IIIA (tumor size > 2
cm) as determined by physical examination and mam-
mography; age 18–70 years; normal cardiac function
determined by electrocardiogram and left ventricular
ejection fraction (L-VEF); World Health Organization
(WHO) performance status 0; adequate contraceptive
method (women of childbearing potential). The exclusion
criteria were: locally advanced disease (stage IIIB) or
inflammatory breast carcinoma; active infection; presence
of distant metastases; any evidence of clinically active
interstitial lung disease; absolute neutrophil count (ANC)
less than 1.5 · 109/l, or platelets less than 100 · 109/l;
serum bilirubin greater than 1.5 times the upper limit of
reference range (ULRR); alanine amino transferase (ALT)
or aspartate amino transferase (AST) greater than 2.5
times the ULRR; any evidence of severe or uncontrolled
systemic disease; concomitant use of phenytoin, carba-
mazepine, rifampicin, barbiturates, or St John’s Wort;
pregnancy or breastfeeding.
Pre-study staging included mammography, chest XR,
bone scan, liver ultrasonography, echocardiography and
hematological blood tests.
The local human investigation committees of partici-
pating institutions approved the protocol; all patients gave
the written informed consent to participate the study.
Study design
At baseline, a large core (14 gauge) breast biopsy for his-
tological diagnosis and for the immunohistochemical
(IHC) analyses of tumor biomarkers was performed.
Eligible patients were therefore randomized to receive
chemotherapy with epirubicin 90 mg/m2 intravenous (iv)
bolus plus paclitaxel 175 mg/m2 iv infusion over 3 h on
day 1 for 4 courses administered every 3 weeks plus:
gefitinib 250 mg orally once daily from day 5 to day 16
of four 3-weekly cycles of chemotherapy (Arm A,
intermittent); or gefitinib 250 mg orally once daily from
days 1 to 21 for four 3-weekly cycles of chemotherapy
(Arm B, continuous); or placebo orally daily for four
3-weekly cycles of chemotherapy (Arm C, control). Arm
B and Arm C were double blinded. The study plan is
showed in Panel 1. Patients underwent surgery within
5 weeks from the administration of the 4th chemotherapy
cycle.
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Chemotherapy was not administered in case of:
WBC < 3 · 109/l, ANC < 1.5 · 109/l, or platelet count
was <100 · 109/l. Epirubicin and paclitaxel doses were
reduced by 25% in case of: febrile neutropenia, grade 4
thrombocytopenia lasting >3 days and/or thrombocytope-
nia associated with bleeding, grade 4 neutropenia lasting
>7 days, grade 3 non hematologic toxicities (except for
nausea/vomiting and alopecia). In case of grade 4 non
hematologic toxicities epirubicin and paclitaxel doses were
reduced by 50% or interrupted. Paclitaxel dose was
reduced by 25% in case of grade 1 neurotoxicity, and
discontinued in case of grade 2 neurotoxicity.
No dose reduction for gefitinib was foreseen. Repeated
dose interruptions were allowed for a maximum of 14 days
in case of: grade 3–4 diarrhea, grade 2 diarrhea with rap-
idly declining ANC, poorly tolerated skin toxicity,
respiratory symptoms suspicious for interstitial lung dis-
ease, any other grade 3–4 toxicity or lower clinically
relevant toxicity. Gefitinib dose was restarted when toxicity
reverted to grade 1.
Study aims
The primary end-point of the study was to evaluate the
inhibition induced by chemotherapy plus gefitinib vs che-
motherapy plus placebo on the EGFR dependent p42/44
MAPK from biopsy to surgery. Secondary aims were to
evaluate the modifications in EGFR and activated/phosphor-
ylated (p)-EGFR expression, in proliferation index, apoptotic
index and VEGF-R (Flk1) expression from biopsy to surgery;
to evaluate the percentage of pCR, and the toxicity of this
combination. pCR was defined as complete disappearance of
invasive carcinoma in both breast and axillary lymph nodes.
Residual DCIS was included in the pCR category.
Pathology
All the specimens from both biopsy and surgery were
centrally analyzed at the Department of Pathology in Mo-
dena for the evaluation of the following parameters: p42/44
MAPK, EGFR, (p)-EGFR, proliferation index (Ki-67),
apoptotic index (TUNEL assay) and VEGFR2 (KDR/Flk1)
expression. A dedicated breast pathologist, blinded to
patient treatment allocation and clinical outcome, reviewed
all paired biopsy and surgical specimens.
Immunohistochemical staining
Tumor specimens has been fixed in 10% neutral-buffered
formalin for 20–28 h before processing and embedding at
local pathology centers in paraffin wax blocks.
The antibody used were Phospho-p44/42 MAP Kinase
(Thr202/Tyr204), Cell Signaling, diluited at 1:30; (p)-EGFR
(Tyr 1068), Cell Signaling, diluted at 1:20; EGFR clone 31G7,
Zymed, diluted at 1:100; VEGFR2 (FLK1), Neomarkers,
diluted at 1:150; Ki 67clone Ki-mib-1 diluted at 1:200.
Immunohistochemical staining was performed according to
the avidin-biotin method, using tissue sections of 3 micron
thickness. After deparaffinization in xylene and graded alco-
hols, epitope retrieval was performed. Antigene retrieval for
p42/44 MAPK, (p)-EGFR, VEGFR2 and Ki-67 was made in
10 mM EDTA buffer (pH 8) in a microwave. Epitope retrieval
for EGFR was made by protease XIV for 10 min. After epi-
tope retrieval, endogenous peroxidase was blocked by 0.3%
hydrogen peroxide for 15 min. Section were incubated with
primary antibody for 30 min at 37C. then with the biotiny-
lated secondary antibody for 20 min at 37C and then in
avidin-biotin complex for a further 45 min. Diaminobenzi-
dine tetrahydrochloride (DAB) was used as chromogen. The
following parameters has been recorded: presence or absence
of immunoreaction (diffuse or focal), cell types exhibiting a
positive reaction (tumor cells, endothelia, stromal cells,
inflammatory cells) and percentage of immunostained cells.
Assessment of the apoptotic index
The sections were stained for apoptosis using the terminal
deoxynucleotidyl transferase biotin-dUTP nick end label-
ing technique. Apoptotic cells were identified by the
C
O
R
E
B
I
O
P
S
Y
A (Intermittent): Epirubicin + Paclitaxel iv day1 + 
Gefitinib 250 mg/die orally (days 5-16) q3 wks x 4 
S
U
R
G
E
R
Y
R
A
N
D
O
M
I
Z
A
T
I
O
N
B (Continuous): Epirubicin + Paclitaxel iv day1 + 
Gefitinib 250 mg/die orally (days 1-21) q3 wks x 4 
C (Control): Epirubicin + Paclitaxel iv day1 + 
placebo orally (days 1-21) q 3 wks x 4 
Panel 1 Treatment plan
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TUNEL method, according the standard procedure inclu-
ded in the Apop Tag Plus In situ Apoptosis Detection Kit
(Chemicon International). The Apoptotic Index (AI) was
defined as the percentage of apoptotic events per cells
population. The AI was assessed by counting at least 3,000
malignant cells randomly selected at 400· magnification.
Statistics
The primary comparison was planned between combined
arms A and B versus arm C. Assuming the mean per-
centage of p42/44 MAPK positive cancer cells x% after
four courses of chemotherapy and placebo, and Y% after
four courses of chemotherapy plus gefitinib (intermittent
and continuous arms combined), 30 subjects per treatment
arm would be sufficient to detect a reduction to a y% of
half of x% at a two sided alpha of 5% with a power of 80%,
and provided the standard deviation of the difference pre-
and post-gefitinib was no more than 0.7 times x%,
assuming a drop out rate of 1/6 and making an allowance
for non-parametric test.
The Wilcoxon rank sum test was used to compare
median differences of biomarker values from baseline to
surgery in Arms A and B pooled and Arm C. All subjects
that were randomised and received the first dose of study
treatment were considered intention-to-treat (ITT) popu-
lation. Safety analysis set is composed of all patients who
received al least the first dose of study treatment (all 90
patients). Chi-square test was used to compare the pro-
portions of patients with various types of toxicity.
The Wilcoxon sign rank matched pairs test was used to
evaluate differences between baseline and surgery bio-
marker expression.
Results
Patients and response
From April 2004 to January 2006, 90 patients from 10
Italian Centers were randomized. Table 1 summarizes
patient characteristics overall, and by treatment arm.
The median age of the whole group was 51 (range
29–69). The clinical stage was IIA in 36 patients (40%),
IIB in 44 patients (49%), and IIIA in 9 patients (10%). One
patient with clinical stage IIIB was wrongly enrolled but
was considered for all the protocol outcomes according to
the ITT analysis. Patients characteristics were balanced
among the 3 treatment arms, with the exception of HER2
and EGFR expression.
Eighty-six out of 90 patients have been submitted to
surgery after primary treatment; reasons for not undergoing
surgery were: one death because of car accident, 1 patient
major protocol deviation and lost to follow up, 1 treatment
Table 1 Patient characteristics overall, and by treatment arm (% of patients)
ALL ARM A ARM B ARM C
Number 90 27 32 31
Median age, years (range) 51 (29–69) 51 (29–68) 46.5 (33–69) 51 (31–66)
Mean T size with breast imaging, cm (range) 3.3 (2–9) 3.2 (2–9) 3.3 (2–6) 3.6 (2–7.5)
Clinical stage*
IIA 40 48.2 34.4 38.7
IIB 49 37 56,2 51.6
IIIA 10 14.8 9.4 6.5
Histologic type
Ductal 81.1 85.2 84.4 74.2
Lobular 5.5 0 6.2 9.7
Other/NA 13.3 14.8 9.4 16.1
Histologic Grade
G2 30 37 22 32
G3 50 52 56 42
NA 20 11 22 26
ER positivity 70 74 64 72
PgR positivity 52 52 42 60
HER2+ 24 30 31 10
EGFR >/= 10% 14 4 11 27
* 1 pt stage IIIB in Arm C
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interruption due to adverse event, and one death due to
myocardial infarction in the operating room.
According to ITT analysis, 46/90 patients (51%)
underwent breast conservative surgery: 17 (63%) in Arm
A, 15 (47%) in Arm B, and 14 (45%) in Arm C. A pCR in
both breast and axillary nodes was observed in 4 patients: 2
in Arm A, 1 in Arm B and C respectively. The pCR rate
was significantly higher in hormone receptor negative
versus positive tumors (12.5% vs 1.5%, P = 0.02). No
significant differences were observed according to HER2
status (pCR rate 9.5% in HER2+ vs 3.2% in HER2,
P = 0.25) or to EGFR expression (pCR rate 6.6% in
EGFR+ vs 4.3% in EGFR, P = 0.70).
Compliance with treatment and toxicity
Overall, 10 patients discontinued the experimental treatment:
1 patient in Arm A for a grade 3 hypertransaminasemia, 4
patients in Arm B (1 treatment and cancer unrelated death; 1
grade 3 hypertransaminasemia; 1 progression of disease; 1
grade 3 skin toxicity), and 5 patients in Arm C (1 grade 2
enteritis; 1 grade 4 hypertransaminasemia; 1 perforative
peritonitis; 1 severe mood alteration requiring carbamaze-
pine; 1 major protocol deviation).
Chemotherapy dose reductions or delays were necessary
in 28% of courses in Arm A, 19% in Arm B and 15% in
Arm C (P = ns).
Grade 3–4 hematologic toxicities per treatment arms are
summarized in Table 2: no significant differences were
observed when comparing the two arms with chemotherapy
plus gefitinib (Arms A and B) versus chemotherapy plus
placebo (Arm C), nor comparing the two different sched-
ules of gefitinib in combination with chemotherapy (Arm A
vs Arm B).
Non hematologic toxicities are summarized in Table 3.
Significantly higher skin and mucosal toxicities were
observed when comparing the two gefitinib Arms (A + B)
vs the placebo arm C (32.2% vs 9.6%, P = 0.018 and
57.6% vs 29.0%, P = 0.009 respectively). Again, no
significant differences were observed when comparing
Arm A vs Arm B (intermittent vs continuous gefitinib).
Biomarker expression
Adding gefitinib to chemotherapy did not result in a
decreased expression of p42/44 MAPK from baseline to
surgery as compared to chemotherapy plus placebo: the
median (min;max) differences in p42/44 MAPK expression
were 5 (70; 90) in combined Arms A + B and 5 (14;
52) in Arm C (P = 0.98). The same observation was found
when comparing Arm A vs Arm B: the median (min;max)
differences were 6.5 (2; 60) and 3 (70; 50) respectively
(P = 0.4870) (Fig. 1).
Similar findings were observed in the expression of the
other tumor biomarkers (EGFR, (p)-EGFR, VEGFR2,
proliferation and apoptosis). No significant differences
were observed comparing the combined Arms A + B vs C,
and comparing Arm A vs B (Table 4).
On the contrary, irrespectively of treatment arm, a sig-
nificant reduction in the expression of tumor biomarkers
from baseline to surgery was observed, with the exception
of EGFR. In particular, the median (min;max) values at
baseline and at surgery were: p42/44 MAPK 7 (0;65) and 1
(0;70) (P < 0.001); (p)-EGFR 0 (0;40) and 0 (0;20)
(P = 0.0019); Ki 67 30 (3;90) and 15 (1;90) (P < 0.0001);
apoptotic index 1.105 (0.05;4.7) and 0.71 (0.1;4.3)
(P = 0.0007); VEGFR2 2 (0;80) and 0 (0;20) (P < 0.001).
The data for p42/44 MAPK, apoptotic index, Ki 67 and
VEGFR2 are represented in Fig. 2.
Discussion
Primary systemic therapy for operable disease represents
the ideal model to test the in vivo effects of targeted agents
on the tumor microenvironment. In fact, the diagnostic
biopsy allows for the evaluation of unperturbed tumor
characteristics, while the measurement of the same
Table 2 Grade 3–4 Hematologic toxicity by treatment arm (Number and % of patients)
ARM A (27 pts) ARM B (32 pts) ARM C (31 pts)
G3 G4 G3 G4 G3 G4
N (%) N (%) N (%) N (%) N (%) N (%)
Leukopenia 1 (3.7) - 1 (3.1) – – –
Neutropenia 3 (11.1) 9 (33.3) 7 (21.8) 9 (28.1) 7 (22.6) 7 (22.6)
Anemia – – 1 (3.1) 1 (3.1) – –
Thrombocytopenia – – – – – –
Febrile neutropenia 2 (7.4) 1 (3.7) 1 (3.1) – 1 (3.2) –
v2-test, P value not significant for A + B vs C and A vs B
Breast Cancer Res Treat (2008) 110:127–134 131
123
biomarkers after therapy gives the opportunity to better
understand the interactions between biomarker modulation
and treatment effects.
This phase II randomized trial was designed on the basis
of a biological primary end point: to evaluate the effect of
chemotherapy plus gefitinib vs chemotherapy plus placebo
on the expression of the EGFR dependent p42/44 MAPK
(also called ERK). The mitogen-activated protein kinase
(MAPK) family is an intracellular pathway that regulates
cell survival and death. In particular, the stress-activated
protein kinases JNK/SAPK and p38MAPK seem to pro-
mote apoptotic signaling in response to chemical and
Table 3 Non-hematologic toxicity by treatment arm (Number and % of patients)
ARM A (27 pts) ARM B (32 pts) ARM C (31 pts)
G1 G2 G3 G1 G2 G3 G1 G2 G3 G4
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Nausea/Vomiting 13 (48.1) 6 (22.2) 2 (7.4) 12 (37.5) 8 (25) – 13 (41.9) 9 (29.0) 1 (3.2) –
Mucositis* 11 (40.7) 6 (22.2) – 10 (31.2) 6 (18.7) 1 (3.1) 4 (12.9) 5 (16.1) – –
Diarrhoea 4 (14.8) 3 (11.1) 1 (3.7) 6 (18.7) 5 (15.6) 1 (3.1) 2 (6.4) 3 (9.6) 2 (6.4) –
Alopecia 1 (3.7) 5 (18.5) 1 (3.7) 3 (9.3) 7 (21.8) 3 (9.3) 4 (12.9) 9 (29.0) 3 (9.6) –
Hepatotoxicity 1 (3.7) – 3 (11.1) – 2 (6.2) 2 (6.2) 1 (3.2) – 1 (3.2) 1 (3.2)
Neurotoxicity 6 (22.2) – 1 (3.7) 7 (21.8) – – 8 (25.8) 3 (9.6) – –
Skin toxicity** 7 (25.9) 2 (7.4) – 2 (6.2) 7 (21.8) 1 (3.1) 3 (9.6) – – –
Allergic reaction 1 (3.7) 1 (3.7) – 1 (3.1) 2 (6.2) 2 (6.2) 1 (3.2) – 1 (3.2) –
Pulmonary 2 (7.4) 1 (3.7) – 5 (15.6) 1 (3.1) – 2 (6.4) – – –
* P = 0.009 Arms A + B vs C
** P = 0.018 Arms A + B vs C
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Fig. 1 Box plots of the
differences in p42/44 MAPK
expression from baseline to
surgery. Panel 1.1: differences
from baseline to surgery in arm
A (light gray plot) and arm B
(grey plot); Wilcoxon rank sum
test, P=0.49. Panel 1.2:
differences from baseline to
surgery in combined arms A and
B (light gray plot) and arm C
(gray plot); Wilcoxon rank sum
test, P=0.98
Table 4 Median differences between pre-treatment biopsy and surgery (min, max)
Biological parameter Arm A Arm B Arm A + B Arm C P-value (A + B vs C) P-value (A vs B)
p42/44 MAPK 6.5 (12;60) 3 (70;50) 5 (70;60) 5 (14;52) 0.78 0.38
EGFR 0 (0;5) 0 (4;20) 0 (4;20) 0 (20;80) 0.95 0.4
(p)-EGFR 0 (0;40) 0 (2;5) 0 (2;40) 0 (0;25) 0.49 0.23
Ki67 1.5 (25;55) 10 (4;65) 6 (25;65) 2.5 (55;63) 0.28 0.06
Tunel 0.47 (3.45;3.16) 0.27 (1.04;2.1) 0.3 (3.45;3.16) 0.31 (3.92;3.6) 1.00 0.69
VEGF-R 1 (2;80) 0 (5;30) 0 (5;80) 0 (3;50) 0.67 0.41
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environmental stress. The mitogen activated protein p42/44
MAPK is activated by extracellular signaling, and its
activation has been associated with cell proliferation and
survival [15–17].
We hypothesized that the addition of the tyrosine kinase
inhibitor of EGFR gefitinib to chemotherapy would result
in an enhanced inhibition of the p42/44 MAPK as com-
pared to chemotherapy plus placebo. Contrary to this
expectation, the inhibition of p42/44 MAPK was not sig-
nificantly different between patients receiving or not
gefitinib. However, a significant inhibition of this intra-
cellular pathway was observed independently by treatment
arm. Therefore, we can hypothesize that chemotherapy by
itself can inhibit the p42/44 MAPK, thus masking the effect
of gefitinib on its specific cellular pathway. The effect of
chemotherapy on the p42/44 MAPK has been extensively
studied on cell lines, however without conclusive results
[18]. In particular, paclitaxel has been shown to increase
the p42/44 MAPK activity, with either enhanced or
decreased apoptosis, as well as no effect [19–21]. There-
fore, whether activation of p42/44 MAPK signaling
represents a protective or proapoptotic response to paclit-
axel exposure remains an unsolved question. Data with
anthracyclines are even more scanty and uncertain [18].
Similarly to that observed for p42/44 MAPK, the
expression of EGFR, (p)-EGFR, VEGFR2 as well as tumor
proliferation (Ki 67) and apoptotic index was not signifi-
cantly modified by adding to chemotherapy gefitinib or
placebo. On the contrary, except for the EGFR, all these
parameters were significantly reduced after therapy,
irrespectively of treatment arm.
Our patient population was not selected nor stratified for
EGFR status. This choice was dictated by the lack of
reproducibility among different laboratories in the EGFR
assay and by the uncertain relation between EGFR
expression and its dependent signaling pathway in breast
cancer [22]. Unfortunately, by chance, in the chemotherapy
plus placebo arm there was a significantly lower percentage
of HER2-positive and a significantly higher percentage of
EGFR-expressing tumors. The most interesting results with
gefitinib derive from a randomized trial comparing preop-
erative gefitinib vs gefitinib plus anastrozole in a patient
population selected for EGFR and ER expression [23]. We
cannot therefore rule out the hypothesis that our results are
influenced by the unselected patient population and the
imbalance in HER-family expression in the three arms.
However, as a matter of fact, the inhibition of the EGFR
dependent pathway, was surprisingly consistent across the
different treatment arms.
The pCR rate was a secondary end point of the study and
was lower than expected.
It is known that the probability of achieving a pCR is
significantly higher in case of lower T size, and negative
hormone receptors. In our study population, the mean T
size was 3.3 cm (range 2–9 cm) and 70% of the patients
had ER positive tumors. These features might in part
account for the low pCR rate. In a randomized trial
comparing preoperative anastrozole + gefitinib vs anas-
trozole in operable breast cancer patients, the combination
resulted in a lower inhibition of ki67, and in a trend for a
lower ORR versus anastrozole alone, thus suggesting a
potential detrimental effect of gefitinib [24]. In our trial
no difference in the pCR rate was observed comparing the
arms with gefitinib plus chemotherapy versus chemo-
therapy plus placebo, therefore it is unlike that gefitinib
had in some way reduced the activity of chemotherapy.
Furthermore, despite the low rate of pCR, we observed an
interesting rate of breast conservative surgery (51%),
2.1: p42/44 MAPK 2.2 Apoptotic index (Tunel test) 
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Fig. 2 Box plots of biomarker
expression from baseline (pink
plots) to surgery (blue plots);
(Wilcoxon signed rank matched
pairs test). Panel 2.1: p42/44
MAPK (P<0.001). Panel 2.2:
Apoptotic Index (Tunel test)
(P=0.0007). Panel 2.3: Ki 67
(P<0.0001). Panel 2.4:
VEGFR2 (P<0.001)
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considering that 60% of the patients were stage IIB or
IIIA at diagnosis.
Overall, treatment was well tolerated, and the toxicity
profile was not dissimilar to that reported for either treat-
ment alone. As expected, the combination of gefitinib plus
chemotherapy (Arms A + B) resulted in a significantly
higher skin and mucosal toxicity as compared to chemo-
therapy plus placebo (Arm C). Unexpectedly, considering
that patients in Arm B received almost doubled dose of
gefitinib (21 daily doses vs 12 daily doses in Arm A) no
differences in toxicity were observed when comparing the
two different schedules of gefitinib administration. In
conclusion, adding gefitinib to chemotherapy does not
result in different effects on the EGFR-dependent pathway,
proliferation, apoptotic index and VEGFR2 expression as
compared to chemotherapy plus placebo, while enhancing
skin and mucosal toxicity. Moreover, the two schedules of
gefitinib (intermittent vs continuous) did not result in sig-
nificantly different biologic effects.
These and other disappointing results obtained both in
advanced and in early disease, suggest that the inhibition of
the EGFR-driven pathway is unlikely to play a key role in
the majority of breast cancers. A better standardization of
EGFR assay, a more precise definition of the role of EGFR
pathway in specific molecular subsets such as triple nega-
tive disease and availability of new ErbB family targeting
agents, are likely to renew the interest in targeting this
signaling pathway in breast cancer.
Acknowledgments This trial was coordinated and supervised by the
principal investigators with funding and organizational support from
the trial sponsor AstraZeneca. The corresponding author had full
access to all the data in the study and had final responsibility for the
decision to submit for publication
References
1. Salomon DS, Brandt R, Ciardiello F et al (1995) Epidermal
growth factor related peptides and their receptors in human
malignancy. Crit Rev Haematol 19:183–232
2. Klijn JG, Berns PM, Schmitz PI et al (1992) The clinical sig-
nificance of epidermal growth factor receptor (EGF-R) in human
breast cancer: a review on 5232 patients. Endocr Rev 13:3–17
3. Tang CK, Gong XQ, Moscatello DK et al (2000) Epidermal
growth factor receptor vIII enhances tumorigenicity in human
breast cancer. Cancer Res 60:3081–3087
4. Khazaie K, Schirrmacher V, Lichtner RB (1993) EGF receptor in
neoplasia and metastasis. Cancer Metastasis Rev 12:255–274
5. Messa C, Russo F, Caruso MG et al (1998) EGF, TGF-alpha, and
EGF-R in human colorectal adenocarcinoma. Acta Oncol
37:285–289
6. Karunagaran D, Tzahar E, Beerli RR et al (1996) ErbB-2 is a
common auxiliary subunit of NDF and EGF receptors: implica-
tions for breast cancer. EMBO J 15:254–264
7. Wakeling AE, Guy SP, Woodburn JR et al (2002) ZD1839 (Iressa):
An orally active inhibitor of epidermal growth factor signaling
with potential for cancer therapy. Cancer Res 62:5749–5754
8. Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib,
an inhibitor of the epidermal growth factor receptor tyrosine
kinase, in symptomatic patients with non-small cell lung cancer:
a randomized trial. JAMA 290:2149–2158
9. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional
randomized phase II trial of gefitinib for previously treated
patients with advanced non-small-cell lung cancer (The IDEAL 1
Trial). J Clin Oncol 21:2237–2246
10. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations
in the epidermal growth factor receptor underlying responsive-
ness of non-small-cell lung cancer to gefitinib. N Engl J Med
350:2129–2139
11. Baselga J, Albanell J, Ruiz A et al (2005) Phase II and tumor
pharmacodynamic study of gefitinib in patients with advanced
breast cancer. J Clin Oncol 23:5323–5333
12. Gasparini G, Sarmiento R, Amici S et al (2005) Gefitinib
(ZD1839) combined with weekly epirubicin in patients with
metastatic breast cancer: a phase I study with biological correlate.
Ann Oncol 16:1867–1873
13. Fountzilas G, Pectasides D, Kalogera-Fountzila A et al (2005)
Paclitaxel and carboplatin as first-line chemotherapy combined
with gefitinib (IRESSA) in patients with advanced breast cancer:
a phase I/II study conducted by the Hellenic Cooperative
Oncology Group. Breast Cancer Res Treat 92:1–9
14. Ciardiello F, Troiani T, Caputo F et al (2006) Phase II study of
gefitinib in combination with docetaxel as first line therapy in
metastatic breast cancer. Br J cancer 94:1604–1609
15. Cobb MH (1999) MAP kinase pathway. Prog Biophys Mol Biol
71:479–500
16. Davis RJ (2000) Signal transduction by the JNK group of MAP
kinases. Cell 103:239–252
17. Ono K, Han J (2000) The p38 signal transduction pathway:
activation and function. Cell Signal 12:1–13
18. Fan M, Chambers TC (2001) Role of mitogen-activated protein
kinases in the response of tumor cells to chemotherapy. Drug
Resist Updat 4:253–267
19. Shtil AA, Mandlekar S, Yu R et al (1999) Differential regulation
of mitogen-activated protein kinases by microtubule-binding
agents in human breast cancer cells. Oncogene; 18:377–384
20. Huang Y, Sheikh MS, Fornace AJ et al (1999) Serine protease
inhibitor TPCK prevents Taxol-induced cell death and blocks c-
Raf-1 and Bcl-2 phosphorylation in human breast carcinoma
cells. Oncogene 18:3431–3439
21. Bacus SS, Gudkov AV, Lowe M et al (2001) Taxol-induced
apoptosis depends on MAP kinase pathway (ERK and p38) and is
independent of p53. Oncogene 20:147–155
22. Chan SK, Hill ME, Gullick WJ (2006) The role of the epidermal
growth factor receptor in breast cancer. Mammary Gland Biol
Neoplasia 11:3–11
23. Polychronis A, Dudley Sinnett H, Hadjiminas D et al (2005)
Preoperative gefitinib versus gefitinib and anastrozole in post-
menopausal patients with oestrogen-receptor positive and
epidermal-growth-factor-receptor-positive primary breast cancer:
a double-blind placebo-controlled phase II randomised trial.
Lancet Oncol 6:383–391
24. Dowsett M, Smith I, Skene A et al (2006) Biological and clinical
outcomes from a phase II placebo-controlled neoadjuvant study
of anastrozole alone or with gefitinib in postmenopausal women
with ER/PgR+ breast cancer. Proc Am Soc Clin Oncol 24:s6
(abstr 515)
134 Breast Cancer Res Treat (2008) 110:127–134
123
